Bruce Wang, MD

Associate Prof In Residence
Department of Medicine - Gastroenterology
+1 415 476-6160
Research Description: 

My lab studies how the different cell types in the liver, in particular the hepatocyte, are generated during development, patterned and maintained during adulthood, and regenerate after injury. Our long-term goals are to improve the understanding of liver disease pathophysiology and develop novel methods of treatment for liver diseases, including cell replacement therapy. Currently, we have two major research focuses: 1) understanding the biology of adult hepatocyte stem cells and 2) developing a liver cell atlas. We take innovative and integrated approaches to address these two areas using the tools of stem cell biology, developmental biology, genomics and tissue engineering.

I also study the porphyrias, a group of inherited diseases related to defects in heme synthesis pathway. I am a member of the Porphyrias Consortium, a NIH sponsored Rare Disease Clinical Research Consortium. The purpose of the network is to integrate translational studies of the porphyrias with clinical trials testing new therapeutics.

Primary Thematic Area: 
Developmental & Stem Cell Biology
Secondary Thematic Area: 
Tissue / Organ Biology & Endocrinology
Research Summary: 
We study how the different cell types in the liver, in particular the hepatocyte, are generated during development, patterned and maintained during adulthood, and regenerate after injury.

Websites

Publications: 

Liver involvement in a large cohort of patients with erythropoietic protoporphyria or X-linked protoporphyria.

Hepatology communications

Levy C, Naik H, Overbey J, Hedstrom K, Wang K, McDonough C, Freeman M, Keel SB, Erwin AL, Dickey AK, Leaf RK, Quigley J, Mazepa M, Wang B, Phillips J, Parker C, McGuire B, Kazamel M, Bonkovsky H, Rudnick S, Anderson KE, Moghe A, Thapar M, Saberi B, Wheeden K, Desnick R, Balwani M, Porphyrias Consortium of the Rare Diseases Clinical Research Network

AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion.

Nature biotechnology

Kim JJ, Kurial SNT, Choksi PK, Nunez M, Lunow-Luke T, Bartel J, Driscoll J, Her CL, Dhillon S, Yue W, Murti A, Mao T, Ramos JN, Tiyaboonchai A, Grompe M, Mattis AN, Syed SM, Wang BM, Maher JJ, Roll GR, Willenbring H

Reducing diagnostic delays in acute hepatic porphyria using health records data and machine learning.

Journal of the American Medical Informatics Association : JAMIA

Bhasuran B, Schmolly K, Kapoor Y, Jayakumar NL, Doan R, Amin J, Meninger S, Cheng N, Deering R, Anderson K, Beaven SW, Wang B, Rudrapatna VA

Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.

Orphanet journal of rare diseases

Sardh E, Balwani M, Rees DC, Anderson KE, Jia G, Sweetser MT, Wang B

Perinatal liver inflammation is associated with persistent elevation of CXCL10 and its canonical receptor CXCR3 on common myeloid progenitors.

bioRxiv : the preprint server for biology

Alkhani A, Baskaran S, Murti A, Rapp B, Levy CS, Wang B, Nijagal A